CareCost Estimate · effective · updated
JZ is the claim-line attestation that zero drug was discarded from a single-dose container. It goes on the administered line, never on a separate line and never with JW. Every Medicare Part B single-dose-container claim has carried JW or JZ since July 1, 2023; a line with neither, or both, rejects.
JZ applies only when the documented dose consumed every single-dose vial opened; whether a line is JZ or JW depends on the vials drawn and the units discarded, and the vial draw and the JZ or JW line for any drug and dose are computed in CareCost Estimate’s billing units calculator (Keytruda 200 mg worked example).
JZ is the mandatory claim-line attestation that zero drug was discarded from a single-dose container. It goes on the administered line — never on a separate line, never paired with JW — whenever the dose drawn equals the total billing units of the single-dose vial(s) opened. Since July 1, 2023, every Medicare Part B single-dose container claim must carry either JW (waste) or JZ (no waste). Since October 1, 2023, Medicare can return a claim as unprocessable when the line carries neither. JZ and JW never go on the same line.
JZ was introduced in the CY 2023 Physician Fee Schedule final rule and implemented by CMS Change Request 13056 (Transmittal R12067CP, MLN Matters MM13056). Billers could use it from January 1, 2023, and it became required on Medicare Part B claims on July 1, 2023. From October 1, 2023, Medicare can return single-dose drug claims that leave both JW and JZ off as unprocessable. JZ is governed by the same authority as JW: CMS Internet-Only Manual Publication 100-04, Chapter 17, §40 (Discarded Drugs and Biologicals).
The statutory hook is Section 90004 of the Infrastructure Investment and Jobs Act of 2021, which directs CMS to recover refunds from manufacturers for unused single-dose-container drug above a threshold. JW captures the wasted units. JZ closes the data gap: by requiring a positive attestation on every no-waste claim, CMS can distinguish a true zero-waste administration from a claim where the biller simply forgot to add JW. Without JZ, the quarterly refund calculations would be biased upward (every missing-modifier claim would look like a no-waste claim by default).
JZ is the dominant scenario for fixed-dose biologics whose standard adult dose matches a whole-vial multiple. Keytruda 200 mg flat (two 100 mg vials), Tysabri 300 mg (one 300 mg vial), Ocrevus 600 mg (two 300 mg vials) and Entyvio 300 mg (one 300 mg vial) generate JZ on nearly every administration. For these drugs, the biller's default expectation should be JZ; a JW claim is the exception, not the rule.
JZ is an attestation that nothing was discarded. CMS says claims without the right JW or JZ modifier may be subject to provider audits, and the discarded amount must be documented in the medical record. A weight-based dose that leaves drug in the last vial is a JW claim, even if billing JZ would be faster.
JW and JZ also do not apply to drugs Medicare does not pay for separately: packaged hospital outpatient drugs (status indicator N), packaged ASC drugs (N1), drugs given in a rural health clinic or FQHC, drugs on an inpatient claim, flu, pneumococcal and COVID-19 vaccines, and incident-to supplies. If the dose is less than one billing unit, bill the full unit with JZ.
JW and JZ are Medicare Part B rules for drugs Medicare pays for separately. Rules below are from the CMS JW/JZ FAQ unless noted.
| Setting or payer | JZ required when nothing is discarded? | Rule |
|---|---|---|
| Medicare Part B, physician office | Yes | Almost every drug given incident to a physician service is paid separately, so every single-dose drug needs JW or JZ. |
| Hospital outpatient (OPPS) | Only for some drugs | Status indicator G or K: yes. Status indicator N (packaged): no. |
| Ambulatory surgery center | Only for some drugs | Payment indicator K2: yes. N1 (packaged): no. |
| Critical access hospital | Yes | Drugs are paid separately in this setting. |
| 340B hospitals | Yes | 340B covered entities still report JW and JZ (Noridian). |
| Pharmacy or supplier that does not give the drug | Yes | Report JZ. Since January 1, 2025, report JW for drug discarded while preparing it. |
| Rural health clinic, FQHC, hospital inpatient | No | Drugs are not paid separately in these settings. |
| Medicare Advantage, Medicaid, commercial plans | Plan rules | The CMS FAQ covers Medicare Part B claims. Other plans set their own rules. Check the plan’s billing policy. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| JZ omitted on single-dose vial | Single-dose container claim shows the administered amount exactly matching vial size(s) but neither JW nor JZ is on the line. Since October 1, 2023, Medicare can return the claim as unprocessable. | Resubmit with JZ appended to the administered line. Appeal language: “Per the CMS JW/JZ modifier FAQs and CMS Change Request 13056, the corrected claim appends modifier JZ to the [J-code] administered line, attesting that zero drug was discarded from the single-dose container(s) used. Administered units = [N] = total billing units of the [M] single-dose vials opened.” |
| JZ + JW on same line (mutually exclusive) | Both modifiers appended to one line. JZ and JW describe opposite scenarios (no discard vs discard) and cannot coexist on a single line. | Resubmit with the correct single modifier. If no waste, retain JZ and remove JW. If waste occurred, restructure as two lines: administered (no modifier) plus discarded (JW). Appeal language: “JZ attests that no drug was discarded and JW reports discarded drug, so the two cannot describe the same line. The corrected claim removes the inappropriate modifier and structures the line(s) per IOM Pub 100-04, Chapter 17, §40.” |
| JZ on multi-dose vial | JZ appended to a line for a drug supplied in a container labeled “Multi-Dose” or “MDV.” Multi-dose vials are outside the scope of the JW/JZ rule regardless of dose-to-vial math. | Resubmit without JZ (and without JW). Appeal language: “Per CMS IOM Pub 100-04, Chapter 17, §40, JZ applies only to single-dose containers as defined by FDA labeling. The product administered is supplied in a multi-dose vial (NDC [X], FDA label designation: Multi-Dose), so no waste-or-no-waste modifier is required.” Attach the FDA package insert page showing the MDV designation. |
| JZ on biosimilar with reference-product J-code | JZ correctly reflects no waste but the base HCPCS reports the reference biologic (e.g., J2778 for Lucentis) rather than the biosimilar actually administered (e.g., Q5128 for Cimerli). The modifier is right; the base code is wrong. | Resubmit with the biosimilar HCPCS on the administered line, JZ retained. Appeal language: “The product administered was [biosimilar name], NDC [X], reportable under HCPCS [Q-code]. JZ reporting rules per IOM Pub 100-04, Chapter 17, §40 apply identically to biosimilars; the corrected claim uses the biosimilar HCPCS on the administered line with JZ attesting to zero discarded drug.” |
| JZ on a claim where chart shows waste | Post-payment audit identifies a JZ-attested claim where the medical record documents leftover drug. JZ was not true for this claim, so the payment for it may be recovered. | Voluntarily refund and recode as a JW two-line construction. Appeal language is not the right tool here — the right tool is correction, repayment, and an internal-controls review. Audit risk language: “Self-disclosure under [payer]'s overpayment policy, with corrected claim reflecting the administered units and a separate JW line for the [Y] discarded units per IOM Pub 100-04, Chapter 17, §40.” |
JZ attests that zero drug was discarded from a single-dose container. JW reports the units of drug that were discarded when leftover did occur. The two are mutually exclusive on a single claim line, and every single-dose container line must carry exactly one of them — never both, never neither.
Since July 1, 2023 (CMS Change Request 13056, MLN Matters MM13056), JZ is required on Medicare Part B claims for separately payable single-dose container drugs when no drug was discarded. Since October 1, 2023, Medicare can return a claim that lacks both JW and JZ as unprocessable.
No. JZ and JW are exclusive to single-dose containers as defined by FDA labeling. If the vial label reads “Multi-Dose” or “MDV,” neither modifier applies, even when the dose lands exactly on the vial size with no residual. CMS says the modifiers are not appropriate for drugs from multiple-dose containers.
JZ is a HCPCS line-level modifier and does not change NDC reporting requirements. The administered line still carries the J-code, NDC, units, and JZ. Mismatches between billed units and NDC package-size math are evaluated independently of JZ; payers can deny for NDC-units mismatch even when JZ is present and correct.
Yes. JZ reporting rules are identical for biosimilars supplied in single-dose containers. The biosimilar HCPCS code (e.g., Q5124 for Byooviz, Q5130 for Fylnetra) replaces the reference J-code, but the modifier convention does not change. If no drug was discarded, append JZ on the administered line.
CMS does not use fractional billing units. If the dose given is less than one billing unit, bill the full unit with JZ (CMS JW/JZ FAQ 11). Otherwise, round the dose up to whole units; if whole units are left over in the vials opened, those go on a separate JW line.
No. JZ and JW are Part B medical-benefit modifiers tied to the discarded-drug refund program under Section 90004 of the Infrastructure Investment and Jobs Act. Part D pharmacy benefit claims do not use JZ. Oral oncology, self-administered injectables, and other Part D drugs follow pharmacy benefit conventions, not the JW/JZ vial-waste reporting scheme.
CMS says claims without the right JW or JZ modifier may be subject to provider audits, and the Infrastructure Act requires CMS to audit these claims periodically. The discarded amount must be documented in the medical record, so a JZ claim whose chart shows leftover drug does not match its own record. Reserve JZ for doses that used every vial opened.
All sources are public CMS and Medicare contractor publications. The methodology by which we resolve source disagreements is described in the Methodology.